These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Blue-gray mucocutaneous discoloration: a new adverse effect of ezogabine. Garin Shkolnik T; Feuerman H; Didkovsky E; Kaplan I; Bergman R; Pavlovsky L; Hodak E JAMA Dermatol; 2014 Sep; 150(9):984-9. PubMed ID: 25006968 [TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of ezogabine (retigabine) in adults with refractory partial-onset seizures: Interim results from two ongoing open-label studies. Gil-Nagel A; Brodie MJ; Leroy R; Cyr T; Hall S; Castiglia M; Twomey C; VanLandingham K Epilepsy Res; 2012 Nov; 102(1-2):117-21. PubMed ID: 22771137 [TBL] [Abstract][Full Text] [Related]
7. Ezogabine (retigabine) and its role in the treatment of partial-onset seizures: a review. Splinter MY Clin Ther; 2012 Sep; 34(9):1845-56.e1. PubMed ID: 22917854 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and tolerability exposure-response relationship of retigabine (ezogabine) immediate-release tablets in patients with partial-onset seizures. Tompson DJ; Crean CS; Reeve R; Berry NS Clin Ther; 2013 Aug; 35(8):1174-1185.e4. PubMed ID: 23916044 [TBL] [Abstract][Full Text] [Related]
10. Safety profile of two novel antiepileptic agents approved for the treatment of refractory partial seizures: ezogabine (retigabine) and perampanel. Faulkner MA; Burke RA Expert Opin Drug Saf; 2013 Nov; 12(6):847-55. PubMed ID: 23883095 [TBL] [Abstract][Full Text] [Related]
11. Ezogabine: an evaluation of its efficacy and safety as adjunctive therapy for partial-onset seizures in adults. Yamada M; Welty TE Ann Pharmacother; 2012 Oct; 46(10):1358-67. PubMed ID: 22991134 [TBL] [Abstract][Full Text] [Related]
12. Multimodal imaging in a severe case of hydroxychloroquine toxicity. Bhavsar KV; Mukkamala LK; Freund KB Ophthalmic Surg Lasers Imaging Retina; 2015 Mar; 46(3):377-9. PubMed ID: 25856825 [TBL] [Abstract][Full Text] [Related]
13. The spectrum of anticonvulsant efficacy of retigabine (ezogabine) in animal models: implications for clinical use. Large CH; Sokal DM; Nehlig A; Gunthorpe MJ; Sankar R; Crean CS; Vanlandingham KE; White HS Epilepsia; 2012 Mar; 53(3):425-36. PubMed ID: 22221318 [TBL] [Abstract][Full Text] [Related]
14. Multimodal imaging in a case of deferoxamine-induced maculopathy. Gelman R; Kiss S; Tsang SH Retin Cases Brief Rep; 2014; 8(4):306-9. PubMed ID: 25372534 [TBL] [Abstract][Full Text] [Related]
15. Adjunctive use of ezogabine/retigabine with either traditional sodium channel blocking antiepileptic drugs (AEDs) or AEDs with other mechanisms of action: Evaluation of efficacy and tolerability. Brodie MJ; French JA; McDonald SA; Lee WJ; Adams B; Scott A; Nohria V; DeRossett S Epilepsy Res; 2014 Jul; 108(5):989-94. PubMed ID: 24726452 [TBL] [Abstract][Full Text] [Related]
16. Ring chromosome 20: a pediatric potassium channelopathy responsive to treatment with ezogabine. Walleigh DJ; Legido A; Valencia I Pediatr Neurol; 2013 Nov; 49(5):368-9. PubMed ID: 23916860 [TBL] [Abstract][Full Text] [Related]
17. Retinal toxicity associated with hydroxychloroquine and chloroquine: risk factors, screening, and progression despite cessation of therapy. Michaelides M; Stover NB; Francis PJ; Weleber RG Arch Ophthalmol; 2011 Jan; 129(1):30-9. PubMed ID: 21220626 [TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of ezogabine/retigabine as adjunctive therapy to specified single antiepileptic medications in an open-label study of adults with partial-onset seizures. Lerche H; Daniluk J; Lotay N; DeRossett S; Edwards S; Brandt C Seizure; 2015 Aug; 30():93-100. PubMed ID: 26216692 [TBL] [Abstract][Full Text] [Related]
19. Update on maculopathy secondary to pentosan polysulfate toxicity. Abou-Jaoude M; Fraser C; Maldonado RS Curr Opin Ophthalmol; 2021 May; 32(3):233-239. PubMed ID: 33710012 [TBL] [Abstract][Full Text] [Related]